Want to see OBIO full AI Analyst Report?
OBIO Stock Chart & Stats
$3.74
$0.10(2.75%)
At close: 4:00 PM EDT
$3.74
$0.10(2.75%)
Day’s Range― - ―
52-Week Range$2.20 - $5.42
Previous Close$3.74
Volume149.34K
Average Volume (3M)423.89K
Market Cap
$238.92M
Enterprise Value$215.58
Total Cash (Recent Filing)$94.40M
Total Debt (Recent Filing)$33.63M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 18, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding59,880,714
10 Day Avg. Volume206,441
30 Day Avg. Volume423,889
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.51
Price to Sales (P/S)4.76
P/FCF Ratio-3.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.40Price Target Upside204.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$548.29K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet CushionDebt is minimal (debt-to-equity ~0.04), giving the company material balance-sheet flexibility relative to peers. For a clinical-stage device company, low leverage reduces near-term interest burden and extends optionality to pursue trials or partnerships before forced dilutive financings.
Very High Gross MarginsReported gross margins near 99% imply strong unit economics for the company’s device-based offerings. If operating expenses are controlled, such high product margins permit rapid improvements to operating profit as revenues scale, supporting long-term margin sustainability once commercial traction is achieved.
Governance Continuity And Incentive PlanShareholder approval of directors and a 2026 equity incentive plan supports management continuity and talent retention. In a capital- and expertise-intensive life-sciences business, consistent governance and stock-based incentives help secure the skills needed to advance clinical programs and negotiate strategic partnerships.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow (~-$54.5M TTM) indicate ongoing runway pressure. For a device developer with long clinical timelines, sustained cash burn increases refinancing and dilution risk and can force program delays or dependence on partner funding unless operating performance materially improves.
Sustained Large Operating LossesConsistent multi-year losses (TTM net loss near -$55M) have driven negative returns and equity erosion (ROE strongly negative). Prolonged unprofitability constrains reinvestment, weakens negotiating leverage with partners, and risks shareholder dilution if external capital is repeatedly required to fund operations.
Revenue Volatility And Recent DeclineRevenue shows high volatility and a steep period-over-period decline, undermining predictability of cash generation. For commercialization-dependent device firms, unstable revenue complicates planning, reduces ability to scale fixed-cost infrastructure, and raises questions about sustainable market adoption absent clearer traction.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.20 and its highest was $5.42 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $238.92M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 16 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.1.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.39.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 59,880,714 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.40 (204.81% Upside)
$11.40 (204.81% Upside)
Hedge Fund Trend
Decreased
By 89.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $158.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
70.46%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings (OBIO) is a biomedical technology company focused on developing device-based therapies aimed at treating cardiovascular and related diseases. The company’s core activities center on advancing and clinically validating its medical device programs and working with larger strategic partners to commercialize them.
OBIO Stock 12 Month Forecast
Average Price Target
$11.40
▲(204.81% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
31.07% Insiders
4.90% Mutual Funds
0.45% Other Institutional Investors
56.33% Public Companies and
Individual Investors